Genelux begins dosing in Phase II ovarian cancer trial

US-based oncolytic immunotherapy developer Genelux has started dosing patients in a Phase II clinical trial (VIRO-15) of its clinical-stage candidate GL-ONC1 to treat recurrent ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news